Mankind Pharma Ltd.
NSE: MANKIND · Healthcare
Sector
Healthcare
Size band
Mid cap
Market cap
84,231cr
P/E
49.4
ROE
15.5%
No price is shown on this page, live or delayed. It records what management said on the earnings call, and the company’s filings.
Measured against
Peer set
Pharmaceuticals & Drugs · largest 12 of 82 measured at Q1 FY27 · financials via Screener| Company | Operating margin | Revenue growth |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 29.0% | 10.5% |
| Divi's Laboratories Ltd. | 41.0% | 27.8% |
| Torrent Pharmaceuticals Ltd. | 34.0% | 54.8% |
| Lupin Ltd. | 30.0% | 32.1% |
| Dr. Reddy's Laboratories Ltd. | 11.0% | −5.5% |
| Cipla Ltd. | 17.0% | 2.3% |
| Zydus Lifesciences Ltd. | 24.0% | 22.0% |
| Mankind Pharma Ltd. | 26.0% | 12.9% |
| Aurobindo Pharma Ltd. | 21.0% | 16.3% |
| Torrent Power Ltd. | 19.0% | 2.8% |
| Alkem Laboratories Ltd. | 20.0% | 10.9% |
| Glenmark Pharmaceuticals Ltd. | 20.0% | 23.1% |
No guidance on record.
This section quotes what management told the market on the quarterly earnings call. We have not transcribed one for Mankind Pharma Ltd..
On air
1 call · outcomes not trackedRecorded as stated on air, with the analyst's SEBI registration status where it was given. Anchor calls carry no registration and are marked. Bharatstox does not make, endorse or repeat these calls, and none of them is our view.
| Channel & show | Aired | Stated target | Stated stop | Outcome |
|---|---|---|---|---|
| CNBC AwaazCNBC Awaax · no registration attached | 28 Aug | +1.8% | -0.7% | still open |
Filings
latest 25 of 346- ESOP/ESOS/ESPS1 Sept 2026
- Please find attached intimation regarding allotment of 49,112 equity shares pursuant to ESOP Plan1 Sept 2026
- General Updates31 Aug 2026
- Please find attached final update on sale of stake of Broadway Hospitality Services Private Limited, a wholly owned subsidiary company.31 Aug 2026
- Other Restructuring26 Aug 2026
- Please find attached outcome of the Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limited, a wholly ....26 Aug 2026
- Outcome of Board Meeting26 Aug 2026
- Please find attached outcome of Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limtied, a wholly ....26 Aug 2026
- Press Release20 Aug 2026
- Copy of Newspaper Publication19 Aug 2026
- Shareholders meeting18 Aug 2026
- General Updates17 Aug 2026
- Completion of realignment of Security Cover in respect of Non-Convertible Debentures.17 Aug 2026
- Acquisition13 Aug 2026
- Appointment10 Aug 2026
- Outcome of Board Meeting10 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates10 Aug 2026
- Shareholders meeting6 Aug 2026
- Shareholders meeting4 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates4 Aug 2026
- Copy of Newspaper Publication31 Jul 2026
- Analysts/Institutional Investor Meet/Con. Call Updates30 Jul 2026
- General Updates30 Jul 2026
- Press Release30 Jul 2026
- Investor Presentation30 Jul 2026
The 25 most recent of 346 filings we hold for MANKIND, back to January 2024. Every filing, by day.
Disclaimer
Guidance is quoted from management commentary on quarterly earnings calls; the words are the company's own and the targets are theirs, not ours. Peer comparisons use quarterly financials sourced from Screener, with every company measured at the same fiscal quarter; the peer set is companies sharing the same industry classification, and comparisons are descriptive, not a ranking or a view. Broadcast calls are reproduced as stated on air, attributed, with the analyst's SEBI registration status where given; they are not our calls and not our view. Filings are reproduced as companies filed them to the NSE and BSE; Bharatstox does not verify, endorse or comment on their contents. This page is for informational and educational purposes only and does not constitute investment advice, research, or a recommendation to buy or sell any security. Investing in securities markets is subject to market risks. Read all related documents carefully before investing.